Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Trial identifies genetic fault that affects treatment response in leukemia patients

A genetic fault has been identified in people with an aggressive type of leukemia that can significantly affect how they respond to treatment.

27 Sep 2017

Existing drugs may be able to improve therapy for chronic myeloid leukemia, mice study shows

Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

26 Sep 2017

Make Sense campaign aims to promote better quality of life for head and neck cancer survivors

On the advent of the 2017 Head and Neck Cancer Awareness Week, the European Cancer Patient Coalition invited patients and policy makers to gather at the European Parliament to promote better quality of life for cancer patients and survivors as part of the Make Sense Campaign.

19 Sep 2017

Modified blood thinner may be first promising method to prevent repercussions after TBI

A chemically modified version of the common blood thinner heparin may be the first promising method of preventing the harmful cascade of destruction to brain tissue that commonly follows traumatic brain injury (TBI), according to new research findings.

13 Sep 2017

FDA approves drug to treat patients with newly diagnosed CD33-positive AML

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).

1 Sep 2017

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer Inc. today announced that the U.S. Food and Drug Administration approved MYLOTARG (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.

1 Sep 2017

Spot Leukaemia campaign launched to reduce delays in diagnosis

A UK leukemia charity, Leukaemia CARE, has launched the Spot Leukaemia campaign to raise awareness of the signs and symptoms of leukemia after a survey revealed that leukemia diagnoses are commonly delayed due to poor understanding.

1 Sep 2017

New research program receives DKK 100 million in funding from Novo Nordisk Foundation

The newly established research program, 'Program for Translational Hematology', has just received DKK 100 million in funding from the Novo Nordisk Foundation.

From Novo Nordisk 24 Aug 2017

Cancer drug may inhibit growth of cysts in patients with inherited form of kidney disease

A cancer drug called bosutinib may inhibit the growth of cysts in patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

24 Aug 2017

Study provides new insight into development of immune cells

In contrast to what has been previously believed, development of blood stem cells to mast cells, a type of specialized immune cell, does not depend on a growth factor called stem cell factor.

10 Aug 2017

FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes

The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.

3 Aug 2017

$New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod$

New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod

The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.

2 Aug 2017

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success and reduce negative side effects.

12 Jul 2017

ERYTECH partners with Queen’s University to advance its product candidate for treating arginase-1 deficiency

ERYTECH Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Queen's University in Canada to advance the preclinical development of ERYTECH's eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism.

12 Jul 2017

Prolonged use of cancer inhibitors can lead to severe cardiovascular problems

Plk1 inhibitors have recently been acknowledged as an "Innovative Therapy for leukaemia" by the US Food and Drug Administration.

10 Jul 2017

Timing of mutations can have effect on health and disease

A single genetic mutation can lead to completely different diseases, depending on the time and location at which the mutation occurs.

30 Jun 2017

Researchers trace origins of AML relapse to rare therapy-resistant stem cells

Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.

29 Jun 2017

PNNL-OHSU scientists part of NCI effort to study about role of proteins in cancer biology

The Department of Energy's Pacific Northwest National Laboratory is part of a nationwide effort to learn more about the role of proteins in cancer biology and to use that information to benefit cancer patients.

28 Jun 2017

Researchers discover how mutations in protein network drive high-risk leukemias

Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies.

14 Jun 2017

Study finds steady decline in severe health problems for childhood cancer survivors

Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time.

5 Jun 2017

Myeloid Leukemia News and Research

Trial identifies genetic fault that affects treatment response in leukemia patients

Existing drugs may be able to improve therapy for chronic myeloid leukemia, mice study shows

Make Sense campaign aims to promote better quality of life for head and neck cancer survivors

Modified blood thinner may be first promising method to prevent repercussions after TBI

FDA approves drug to treat patients with newly diagnosed CD33-positive AML

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Spot Leukaemia campaign launched to reduce delays in diagnosis

New research program receives DKK 100 million in funding from Novo Nordisk Foundation

Cancer drug may inhibit growth of cysts in patients with inherited form of kidney disease

Study provides new insight into development of immune cells

FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes

New drug Idhifa for patients with refractory acute myeloid leukemia (AML) gets FDA nod

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

ERYTECH partners with Queen’s University to advance its product candidate for treating arginase-1 deficiency

Prolonged use of cancer inhibitors can lead to severe cardiovascular problems

Timing of mutations can have effect on health and disease

Researchers trace origins of AML relapse to rare therapy-resistant stem cells

PNNL-OHSU scientists part of NCI effort to study about role of proteins in cancer biology

Researchers discover how mutations in protein network drive high-risk leukemias

Study finds steady decline in severe health problems for childhood cancer survivors

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News